Sugi Predict

Sugi Predict / Compounds / SCHEMBL2237410

SCHEMBL2237410

SCHEMBL2237410

COc1cc(NC2=C(Cl)C(=O)c3ccccc3C2=O)ccc1S(=O)(=O)Nc1cccc(C)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 7/20 0.55
▸ KMT2A Q03164 7/20 0.55
▸ MAPT P10636 5/20 0.51
▸ HTT P42858 4/20 0.51
▸ RAB9A P51151 4/20 0.51
▸ NPC1 O15118 3/20 0.51
▸ MITF O75030 2/20 0.51
▸ SMN1; SMN2 Q16637 6/20 0.51
▸ NPSR1 Q6W5P4 3/20 0.51
▸ ADORA2A P29274 1/20 0.48
▸ ALPL P05186 3/20 0.47
▸ ALDH1A1 P00352 5/20 0.47
▸ MAPK1 P28482 4/20 0.46
▸ ATM Q13315 2/20 0.46
▸ LMNA P02545 2/20 0.46
▸ GAA P10253 2/20 0.46
▸ XBP1 P17861 1/20 0.46
▸ CDC25A P30304 2/20 0.46
▸ CDC25B P30305 2/20 0.46
▸ MAP2K7 O14733 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2243847 0.90 HTT (0.61) MEN1KMT2AMAPTHTTRAB9A
SCHEMBL2244992 0.86 CYP19A1 (0.55) MEN1KMT2AMAPTHTTRAB9A
SCHEMBL2241648 0.84 MEN1 (0.50) MEN1KMT2AMAPTHTTRAB9A
SCHEMBL2246284 0.82 MAPT (0.61) MEN1KMT2AMAPTHTTRAB9A
SCHEMBL15906856 0.81 MAPT (0.61) MEN1KMT2AMAPTHTTRAB9A
SCHEMBL12283197 0.78 MAPT (0.60) MEN1KMT2AMAPTHTTRAB9A
SCHEMBL18424314 0.76 CYP19A1 (0.66) MEN1KMT2AMAPTHTTRAB9A
SCHEMBL15906855 0.76 MAPT (0.60) MEN1KMT2AMAPTHTTRAB9A
SCHEMBL2241338 0.75 ALDH1A1 (0.59) MEN1KMT2AMAPTHTTRAB9A
SCHEMBL2243946 0.75 KMT2A (0.67) MEN1KMT2AMAPTHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8673910-B2 Proteasome inhibitors for selectively inducing apoptosis in cancer cells H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE (US) 2014-03-18 — — US disclosed
US-8673910-B2 Proteasome inhibitors for selectively inducing apoptosis in cancer cells H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE (US) 2014-03-18 — — US disclosed
US-20110201609-A1 PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE (US) 2011-08-18 — — US disclosed
US-20110201609-A1 PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE (US) 2011-08-18 — — US disclosed
WO-2010005534-A2 PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2010-01-14 — — WO disclosed
WO-2010005534-A2 PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2010-01-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201609-A1 PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS PSMB7, PSMD7, PSMB6 MEN1 4575/4885KMT2A 2094/4885MAPT 4401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.